nucleoside analogues + interferon

This is a combination therapy consisting of nucleoside analogues and interferon, primarily used in the treatment of chronic hepatitis B and investigated for other viral infections. Nucleoside analogues are small molecule antivirals that inhibit viral DNA polymerase, thereby blocking viral replication. Interferons are cytokines with immunomodulatory and antiviral properties; they enhance the immune response against infected cells by inducing antiviral proteins and promoting cellular immunity. The combination aims to leverage the direct antiviral effect of nucleoside analogues with the immunostimulatory action of interferon for potentially greater efficacy than either agent alone. Clinical studies have shown that this combination can result in greater suppression of hepatitis B virus (HBV) replication compared to monotherapy, though improvements in sustained off-treatment response rates remain limited[1][2][5][7]. The approach has also been explored for other viruses such as Ebola in preclinical models[3].

Other names

pegylated interferon alfa + nucleoside analogsPEG-IFN-α + nucleoside analogspeginterferon alpha + nucleoside analogs